Can prostate-pathology AI generalise to Iraqi patients?
Three research models trained outside Iraq showed strong agreement with pathologists on 339 biopsy slides from 185 patients in Erbil. The result supports local validation, not autonomous diagnosis or immediate clinical deployment.
The short version
- What happened
- The retrospective consecutive series contained 339 slides from 185 patients treated in Erbil from 2013 to 2024; each slide was scanned on three devices, creating 1,017 whole-slide images.
- Who it affects
- Pathologists may gain a practical route to test AI locally before committing to full laboratory digitisation.
- What remains unproven
- This was a retrospective single-hospital cohort of 185 patients and 339 slides, not a prospective clinical deployment.
Keep in mind
This was a retrospective single-hospital cohort of 185 patients and 339 slides, not a prospective clinical deployment.
The pathologist comparison used 59 slides and was not designed to establish equivalence or non-inferiority.
Nine highly discrepant slides lacked the immunohistochemistry needed for an unequivocal reference diagnosis.
Only seven slides were ISUP grade group 1, limiting assessment of low-grade cancer versus benign mimics.
All three scanner datasets came from the same physical slides scanned at one site, so laboratory-to-laboratory variation remains untested.
The systems are research algorithms without regulatory approval for clinical diagnosis.
Source analysis · 3 linked sources. Primary analysed source date: 10 October 2026.
Read the full report · 7 min The evidence, methods, implications and limitations
The answer: the models travelled better than many clinical AI systems do, but they are not ready to diagnose patients
Three pathology AI systems trained outside Iraq produced strong cancer-detection and grading results on prostate biopsies from the Kurdistan Region. The best task-specific model reached an area under the receiver operating characteristic curve of 0.966 for separating malignant from benign slides. Across the three models, sensitivity was 97.1% to 98.9%. Their average agreement with pathologists on ISUP grade was close to the agreement among pathologists in the study's 59-slide, three-reader subset.
That is meaningful external-validation evidence because geographic, laboratory, patient and scanner data were separate from the systems' development material. It is not evidence that a laboratory can remove human review, that treatment decisions improve, or that errors are acceptable in practice. The authors explicitly state that the systems are research algorithms without CE-IVD or US FDA approval. The safest interpretation is that local prospective evaluation is now more credible—not that deployment has been proved safe.[1]
What was tested and who was represented
Researchers retrieved a consecutive series of prostate core-needle biopsies from PAR Private Hospital in Erbil. The archive covered patients investigated for suspected adenocarcinoma between mid-2013 and mid-2024. After excluding prostatectomy and transurethral-resection material, the final cohort included 339 glass slides from 185 patients. The mean age was 68 years, with a range from 33 to 95. One pathologist graded all 339 slides, a second graded 337, and a uropathologist independently reviewed a stratified 59-slide subset plus difficult discrepant cases.
Each physical slide was digitised on two high-throughput scanners and a compact Grundium device, yielding 1,017 whole-slide images. The three AI pipelines used the same attention-based multiple-instance framework but different feature encoders: a model trained specifically on prostate biopsies, plus the UNI and Virchow2 foundation models. Development used 51,247 whole-slide images from Sweden and Norway and earlier validation used 25,601 images from 15 European and Australian clinical sites. The Iraqi material was not used to tune or recalibrate them.[1][2][3]
The headline numbers—and the errors behind them
Against the primary pathologist, cancer-detection AUC ranged from 0.916 for UNI to 0.966 for the task-specific system. Sensitivity was high for all three, but specificity separated them: 94.5% for the task-specific model, 85.4% for UNI and 88.4% for Virchow2. That difference matters in daily work because false-positive calls can force pathologists to re-examine benign glands, adding workload rather than relieving it. Grading agreement also favoured the task-specific system, with quadratically weighted kappa of 0.869 for ISUP grade compared with 0.788 for UNI.
The prespecified marked-error review is more informative than a single average. Across 337 slides read by the first two pathologists, the task-specific, UNI and Virchow2 models made five, 16 and seven marked errors respectively under a definition that included calling a benign slide ISUP grade 2 or higher, or missing a grade-2-or-higher cancer as benign. When a third pathologist re-read slides on which at least two models made marked errors, many apparent discrepancies changed under that reference. All nine difficult slides would have required immunohistochemistry for a definitive diagnosis, showing how an uncertain human reference constrains claims about machine accuracy.[1]
A compact scanner may lower the cost of local validation
Predictions were consistent when the same slides were scanned on three devices. Average cross-scanner quadratically weighted kappa for ISUP grade was 0.956 for the task-specific model, 0.905 for UNI and 0.929 for Virchow2. Most remaining differences were one-step grade shifts. This result is useful for hospitals that cannot justify a full digital-pathology estate before seeing whether AI performs on their own tissue preparation and staining workflow.
A compact scanner could support a bounded validation project without implying that the rest of the operational stack is solved. Slides in this study were still scanned at one Swedish site, so differences in local staff, temperature, maintenance and laboratory procedures were not tested. The paper also reports prior energy measurements of 0.63 watt-hours per biopsy for the task-specific model, 6.74 for UNI and 22.09 for Virchow2. Those comparisons reinforce that a larger foundation model is not automatically the most practical or accurate option for a resource-constrained laboratory.[1]
What this changes for pathologists and patients
For pathologists, the study supports a staged approach: digitise a representative local set, compare model outputs with blinded readers, inspect clinically serious disagreements and measure the added review burden before any live use. A system with high sensitivity but lower specificity may create queues of false alarms. A smaller model may be easier to run on premises, which can reduce cloud cost and support local data control, but it still needs version control, calibration checks, downtime procedures and a named clinician accountable for the final report.
For patients, the potential benefit is more consistent access to specialist review where pathology capacity is limited. The study does not show faster diagnosis, fewer repeat biopsies, better treatment selection or improved survival. It also cannot separate biological population differences from slide preparation and laboratory practice. Presenting the result as proof of clinical benefit would skip the outcomes that matter most to patients and could encourage use before errors, escalation routes and responsibility are understood.[1]
Limits, disclosures and evidence that would change the assessment
The cohort came from one private hospital and contained relatively few low-grade ISUP group 1 slides—seven of 339. Sample size reflected the eligible archive rather than a formal power calculation. No molecular characterisation was available, no immunohistochemistry resolved the nine most difficult cases, and no patient outcome served as an objective reference. The comparison with pathologist agreement was not designed to demonstrate statistical equivalence or non-inferiority. The multi-scanner test reused the same physical slides and one scanning site rather than independent routine laboratories.
Funding included Swedish research foundations, cancer funding and national computing infrastructure; the paper reports no product deployment trial. The openly shared image set and outputs make replication possible. Confidence would rise with prospective multi-hospital validation in Iraq and neighbouring countries, locked thresholds, commercial comparator systems, workload and turnaround-time measures, and follow-up against treatment or outcome data. A controlled clinical study showing fewer consequential errors without extra review burden would change this from promising technical generalisation into evidence for patient benefit.[1][2][3]